pilsicainide plasma concentration via inhibition of OCT2 transporter; has not been studied. Dofetilide or pilsicainide with dolutegravir is contraindicated due to potential toxicity caused by high dofetilide or pilsicainide concentration. Oxcarbazepine Dolutegravir Co-administration with these Phenytoin metabolic inducers may decrease Phenobarbital dolutegravir plasma concentration Carbamazepine and has not been studied. St. John’s wort with these metabolic inducers should be avoided. Antacids containing Dolutegravir Co-administration of antacids polyvalent cations AUC 74% containing polyvalent cations (e.g., Mg, Al) Cmax 72% decreased dolutegravir plasma C24 74% concentration. Dolutegravir is recommended to be administered 2 hours before or 6 hours after taking antacid products containing polyvalent cations. Calcium Dolutegravir TRIUMEQ is recommended to be supplements AUC 39% administered 2 hours before or Cmax 37% 6 hours after taking products C24 39% containing calcium, or alternatively, administer with food. Iron supplements Dolutegravir TRIUMEQ is recommended to be AUC 54% administered 2 hours before or Cmax 57% 6 hours after taking products C24 56% containing iron, or alternatively, administer with food. Metformin Metformin Co-administration of dolutegravir has the potential to increase metformin plasma concentration via inhibition of OCT2 transporter; co-administration has not been studied. Lower metformin doses may be considered for patients treated with dolutegravir and metformin. Rifampicin Dolutegravir Rifampicin decreased dolutegravir AUC 54% plasma concentration. Since the Cmax 43% dose of dolutegravir is 50 mg twice C 72% daily when co-administered with rifampicin, the co-administration of rifampicin with TRIUMEQ is not recommended. Oral contraceptives Effect of dolutegravir: Dolutegravir did not change ethinyl (Ethinyl estradiol EE estradiol and norelgestromin plasma (EE) and AUC 3% concentrations to a clinically relevant extent. No dose adjustment of oral
pilsicainide plasma concentration via inhibition of OCT2 transporter; has not been studied. Dofetilide or pilsicainide with dolutegravir is contraindicated due to potential toxicity caused by high dofetilide or pilsicainide concentration. Oxcarbazepine Phenytoin Phenobarbital Carbamazepine St. John’s wort Dolutegravir Co-administration with these metabolic inducers may decrease dolutegravir plasma concentration and has not been studied. with these metabolic inducers should be avoided. Antacids containing polyvalent cations (e.g., Mg, Al) Dolutegravir AUC 74% Cmax 72% C24 74% Co-administration of antacids containing polyvalent cations decreased dolutegravir plasma concentration. Dolutegravir is recommended to be administered 2 hours before or 6 hours after taking antacid products containing polyvalent cations. Calcium supplements Dolutegravir AUC 39% Cmax 37% C24 39% TRIUMEQ is recommended to be administered 2 hours before or 6 hours after taking products containing calcium, or alternatively, administer with food. Iron supplements Dolutegravir AUC 54% Cmax 57% C24 56% TRIUMEQ is recommended to be administered 2 hours before or 6 hours after taking products containing iron, or alternatively, administer with food. Metformin Metformin Co-administration of dolutegravir has the potential to increase metformin plasma concentration via inhibition of OCT2 transporter; co-administration has not been studied. Lower metformin doses may be considered for patients treated with dolutegravir and metformin. Rifampicin Dolutegravir AUC 54% Cmax 43% C 72% Rifampicin decreased dolutegravir plasma concentration. Since the dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin, the co-administration of rifampicin with TRIUMEQ is not recommended. Oral contraceptives (Ethinyl estradiol (EE) and Effect of dolutegravir: EE AUC 3% Dolutegravir did not change ethinyl estradiol and norelgestromin plasma concentrations to a clinically relevant extent. No dose adjustment of oral
auspar-dolutegravir-sodium-abacavir-sulfate-lamivudine-150519-pi.docx